| Recruiting | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cance NCT07147231 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumor NCT07318805 | Pfizer | Phase 1 |
| Recruiting | Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refr NCT07130903 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Recruiting | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLF NCT06696768 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastat NCT06336902 | University of Southern California | Phase 1 |
| Withdrawn | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met NCT06575725 | City of Hope Medical Center | Phase 2 |
| Recruiting | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encor NCT06102902 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capec NCT06195670 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Withdrawn | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cance NCT05356897 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colo NCT05673148 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic NCT05672316 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Micro NCT05627635 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Withdrawn | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer NCT04119830 | Roswell Park Cancer Institute | Phase 2 |
| Completed | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer NCT05130060 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regim NCT05312398 | University of Campania Luigi Vanvitelli | Phase 2 |
| Recruiting | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Color NCT04511039 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Trea NCT04729322 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Col NCT05869097 | Hunan Cancer Hospital | — |
| Terminated | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430 | University of California, San Francisco | Phase 1 |
| Unknown | Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mism NCT04483219 | China Medical University, China | Phase 2 |
| Completed | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast NCT04362839 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic NCT04117945 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer NCT05942768 | Hunan Cancer Hospital | — |
| Completed | Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC NCT06031376 | Hunan Cancer Hospital | — |
| Terminated | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Ca NCT03610490 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or NCT02997228 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer NCT03087071 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer NCT03043313 | Seagen Inc. | Phase 2 |
| Active Not Recruiting | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer NCT02600949 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary T NCT02599324 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy NCT06083974 | Assiut University | — |
| Completed | Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma NCT02023333 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma NCT01639131 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With NCT01900717 | Centre Hospitalier Universitaire Dijon | Phase 2 |